All In Biotech

Drug Trial Radar · NCT03426995

First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699

A Randomised, Double-blind (Sponsor Open), Placebo-controlled, Three Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699 in Healthy Male Participants

Last checked: Nov 19, 2026Latest source record: Dec 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

48

Actual

Start

Mar 13, 2018

Primary completion

May 2, 2019

Study completion May 2, 2019

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Feb 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This FTIH study, intends to identify the doses of GSK3358699, which are well tolerated by the subjects whilst delivering a robust pharmacodynamic (PD) response. This study will evaluate the safety, tolerability, pharmacokinetic (PK) and PD profile of single (in both fed and fasted states) and multiple ascending doses of GSK3358699 in healthy male subjects within a pre-defined and controlled pharmacodynamic and pharmacokinetic range for each cohort. It also intends to understand the effect of GSK3358699 on systemic markers of inflammation following low dose in vivo lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) challenge and local inflammation in cantharidin-induced blisters. The study has been carefully designed to explore the in vivo biology of the target and the potential for the study drug to become a transformative medicine for subjects in multiple immuno-inflammatory disease indications.

Conditions

  • Arthritis, Rheumatoid

Interventions

  • PlaceboDrug

    Placebo will be administered as a matching oral solution or matching capsule to study drug GSK3358699, during Part A and C once daily

  • GSK3358699Drug

    GSK3358699, will be administered from 1 mg to 45 mg as an oral solution (1 to 10 mg) or as a capsule (3 to 45 mg), in Part A, B and Part C once daily.

  • GM-CSFBiological

    The GM-CSF will be administered as an intravenous infusion to subjects as 60 microgram per meter\^2 in Part A (Day 1) and Part C (Day 14).This will be administered for 2 hours approximately, no later than 24 hours post -dose of the GSK3358699 or placebo in Part C

  • LPSBiological

    LPS will be administered as an intravenous injection to subjects not exceeding 0.75 nanogram per kilogram in Part A (Day 1) and Part C (Day 14). This will be administered no later than 24 hours post -dose of the GSK3358699 or placebo in Part C.

  • CantharidinOther

    This will be applied as a topical application with 0.7% cantharidin liquid which will be diluted with acetone to 0.2%.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to Day 193
  2. Part B: Number of Participants With AEs and SAEsTime frame: Up to Day 30
  3. Part C: Number of Participants With AEs and SAEsTime frame: Up to Day 49
  4. Part A: Number of Participants With Worst Case Chemistry Results by Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to BaselineTime frame: Up to Day 193
  5. Part A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to BaselineTime frame: Up to Day 193
  6. Part B: Number of Participants With Worst Case Chemistry Results by PCI Criteria Post-Baseline Relative to BaselineTime frame: Up to Day 30
  7. Part B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to BaselineTime frame: Up to Day 30
  8. Part C: Number of Participants With Worst Case Chemistry Results by PCI Criteria Post-Baseline Relative to BaselineTime frame: Up to Day 28
  9. Part C: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to BaselineTime frame: Up to Day 28
  10. Part A: Number of Participants With Worst Case Hematology Results by PCI Criteria Post-Baseline Relative to BaselineTime frame: Up to Day 193
  11. Part A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to BaselineTime frame: Up to Day 193
  12. Part B: Number of Participants With Worst Case Hematology Results by PCI Criteria Post-Baseline Relative to BaselineTime frame: Up to Day 30
  13. Part B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to BaselineTime frame: Up to Day 30
  14. Part C: Number of Participants With Worst Case Hematology Results by PCI Criteria Post-Baseline Relative to BaselineTime frame: Up to Day 28
  15. Part C: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to BaselineTime frame: Up to Day 28
  16. Part A: Number of Participants With Abnormal Urinalysis ParametersTime frame: Up to Day 193
  17. Part B: Number of Participants With Abnormal Urinalysis ParametersTime frame: Up to Day 30
  18. Part C: Number of Participants With Abnormal Urinalysis ParametersTime frame: Up to Day 28
  19. Part A: Number of Participants With Worst Case Vital Sign Results by PCI Criteria Post-Baseline Relative to BaselineTime frame: Up to Day 193
  20. Part B: Number of Participants With Worst Case Vital Sign Results by PCI Criteria Post-Baseline Relative to BaselineTime frame: Up to Day 30
  21. Part C: Number of Participants With Worst Case Vital Sign Results by PCI Criteria Post-Baseline Relative to BaselineTime frame: Up to Day 49
  22. Part A: Number of Participants With Worst Case Post-Baseline Abnormal Electrocardiogram (ECG) FindingsTime frame: Up to Day 193
  23. Part B: Number of Participants With Worst Case Post-Baseline Abnormal ECG FindingsTime frame: Up to Day 30
  24. Part C: Number of Participants With Worst Case Post-Baseline Abnormal ECG FindingsTime frame: Up to Day 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Cambridge, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.